Dr. David S Siegel
Claim this profileHackensack University Medical Center
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
10 reported clinical trials
25 drugs studied
Area of expertise
1Multiple Myeloma
t(4;14) positive
GOF mutation in MMSET positive
2Plasma Cell Neoplasm
t(4;14) positive
GOF mutation in MMSET positive
Affiliated Hospitals
Clinical Trials David S Siegel is currently running
MMSET Inhibitor
for Multiple Myeloma
This trial tests a new pill that blocks an enzyme to help treat adults with a hard-to-treat type of blood cancer. The goal is to see if it is safe and effective.
Recruiting1 award Phase 113 criteria
CC-92480 + Other Drugs
for Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Recruiting2 awards Phase 1 & 25 criteria
More about David S Siegel
Clinical Trial Related7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments David S Siegel has experience with
- Dexamethasone
- Bortezomib
- Carfilzomib
- Lenalidomide
- CC-220
- Vorinostat
Breakdown of trials David S Siegel has run
Multiple Myeloma
Plasma Cell Neoplasm
Squamous Cell Carcinoma
Cancer
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does David S Siegel specialize in?
Is David S Siegel currently recruiting for clinical trials?
Are there any treatments that David S Siegel has studied deeply?
What is the best way to schedule an appointment with David S Siegel?
What is the office address of David S Siegel?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.